JP5474792B2 - 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 - Google Patents

亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 Download PDF

Info

Publication number
JP5474792B2
JP5474792B2 JP2010524063A JP2010524063A JP5474792B2 JP 5474792 B2 JP5474792 B2 JP 5474792B2 JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010524063 A JP2010524063 A JP 2010524063A JP 5474792 B2 JP5474792 B2 JP 5474792B2
Authority
JP
Japan
Prior art keywords
compound
mmol
composition
cyclodextrin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010524063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539082A (ja
JP2010539082A5 (enExample
Inventor
ツァイ，シオン
チアン，チャンクン
チャイ，ハイシャオ
Original Assignee
キュリス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュリス，インコーポレイテッド filed Critical キュリス，インコーポレイテッド
Publication of JP2010539082A publication Critical patent/JP2010539082A/ja
Publication of JP2010539082A5 publication Critical patent/JP2010539082A5/ja
Application granted granted Critical
Publication of JP5474792B2 publication Critical patent/JP5474792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2010524063A 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 Expired - Fee Related JP5474792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97105607P 2007-09-10 2007-09-10
US60/971,056 2007-09-10
PCT/US2008/056393 WO2009035718A1 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Publications (3)

Publication Number Publication Date
JP2010539082A JP2010539082A (ja) 2010-12-16
JP2010539082A5 JP2010539082A5 (enExample) 2011-03-24
JP5474792B2 true JP5474792B2 (ja) 2014-04-16

Family

ID=40452375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524063A Expired - Fee Related JP5474792B2 (ja) 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体

Country Status (7)

Country Link
US (3) US7846938B2 (enExample)
EP (1) EP2190287B1 (enExample)
JP (1) JP5474792B2 (enExample)
AU (1) AU2008299896B2 (enExample)
CA (1) CA2698944C (enExample)
ES (1) ES2526718T3 (enExample)
WO (1) WO2009035718A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503857A (ja) * 2021-01-20 2024-01-29 ライトックス リミテッド 保護されたｈｄａｃ（ヒストン脱アセチル化酵素）阻害剤

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101570516B (zh) * 2009-04-14 2011-01-05 重庆威尔德·浩瑞医药化工有限公司 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
EP2685980B1 (en) 2011-03-17 2017-12-06 The Trustees Of The University Of Pennsylvania Methods and use of bifunctional enzyme-building clamp-shaped molecules
WO2012125904A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of egfr
US20140229256A1 (en) 2013-02-11 2014-08-14 Solutran Product substantiation using approved product list system and method
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
CA2846066A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2013159698A1 (zh) * 2012-04-26 2013-10-31 深圳信立泰药业股份有限公司 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
US10552861B2 (en) 2013-02-11 2020-02-04 Solutran, Inc. Dual redemption path with shared benefits system and method
MY182793A (en) * 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN105693630B (zh) * 2016-03-10 2018-02-16 田静 一种吉非替尼中间体的制备方法
EP4025559A4 (en) * 2019-09-08 2023-05-10 Hadasit Medical Research Services and Development Ltd. ANTIFIBROTIC COMPOUNDS AND USES THEREOF
US12100049B2 (en) 2020-06-05 2024-09-24 Soltran, LLC Filtered POS processing of services
US12530346B2 (en) 2021-12-24 2026-01-20 Solutran, LLC Data transmission filtering through a customized filter list

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
ATE174908T1 (de) * 1993-05-26 1999-01-15 Sumitomo Pharma Chinazolinonderivate
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE60214828T2 (de) 2001-02-26 2007-09-06 Mcgill University, Montreal Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben
CN1688549A (zh) 2002-08-23 2005-10-26 麒麟麦酒株式会社 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122199A (ko) * 2003-01-23 2005-12-28 티.케이. 시그널 리미티드 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005097134A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
MX2007012836A (es) 2005-04-14 2008-01-11 Novartis Vaccines & Diagnostic 2-amino-quinazolin-5-onas como inhibidores de la familia hsp90 que son utiles en el tratamiento de enfermedades de proliferacion.
ITMI20050729A1 (it) * 2005-04-22 2006-10-23 Endura Spa Nuova formulazione biologicamente attiva
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US8604044B2 (en) * 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2061469B8 (en) 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2049483A2 (en) 2006-10-28 2009-04-22 Methylgene, Inc. Inhibitors of histone deacetylase
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503857A (ja) * 2021-01-20 2024-01-29 ライトックス リミテッド 保護されたｈｄａｃ（ヒストン脱アセチル化酵素）阻害剤
JP7831858B2 (ja) 2021-01-20 2026-03-17 ライトックス リミテッド 保護されたｈｄａｃ（ヒストン脱アセチル化酵素）阻害剤

Also Published As

Publication number Publication date
JP2010539082A (ja) 2010-12-16
CA2698944A1 (en) 2009-03-19
ES2526718T3 (es) 2015-01-14
HK1144532A1 (en) 2011-02-25
US20090076022A1 (en) 2009-03-19
AU2008299896B2 (en) 2012-02-02
US8846912B2 (en) 2014-09-30
AU2008299896A1 (en) 2009-03-19
US7846938B2 (en) 2010-12-07
EP2190287A1 (en) 2010-06-02
CA2698944C (en) 2015-06-16
US20130338167A1 (en) 2013-12-19
EP2190287B1 (en) 2014-10-29
WO2009035718A1 (en) 2009-03-19
US20110053963A1 (en) 2011-03-03
EP2190287A4 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
JP2010539082A (ja) 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体
TWI495470B (zh) 含鋅結合位之喹唑啉表皮生長因子受體抑制劑
US7547781B2 (en) Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7977347B2 (en) Quinazoline based EGFR inhibitors
US8518910B2 (en) Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2012202433A1 (en) Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety
HK1144532B (en) Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
WO2013159698A1 (zh) 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140205

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees